Analysis of the epidemiological characteristics of rifampicin-resistant pulmonary tuberculosis in Ganzhou, Jiangxi from 2019 to 2020

doi:10.3969/j.issn.1000-6621.2021.12.010

Abstract

Abstract:

Objective Analysis of the epidemic characteristics of rifampicin-resistant pulmonary tuberculosis (“RR-TB” for short) in Ganzhou, Jiangxi from 2019 to 2020. Methods The data of medical record information and drug resistance of registered patients with tuberculosis in Ganzhou City from January 1, 2019 to December 31, 2020 were derived from the Tuberculosis Management Information System, a subsystem of China Disease Control and Prevention Information System. The status of cases tested for resistance and epidemiological characteristics of RR-TB cases were analyzed. Results Among the 10508 pulmonary tuberculosis patients who registered in Ganzhou from 2019 to 2020, there were 5897 bacteriologically confirmed cases. The proportion of bacteriologically confirmed tuberculosis cases tested for rifampicin resistance was 93.18% (5495/5897), and the prevalence of rifampicin resistance was 5.55% (305/5495). The proportion of RR-TB cases from new bacteriologically confirmed retreatment bacteriologically confirmed tuberculosis cases and from retreatment bacteriologically confirmed tuberculosis cases were 49.51% (151/305) and 50.49% (154/305), respectively. The prevalence of rifampicin resistance among who aged 20-59 years (6.25% (199/3186)) was significantly higher than that among who aged 0-19 years (3.74% (8/214)) and who aged greater than 60 years (4.68% (98/2095));the prevalence of rifampicin resistance among Nankang District (9.06% (30/331)) of urban and neighboring suburbs was significantly higher than that among Shicheng County (1.35% (3/222)) of outside suburban district. The differences were statistically significant (the Chi Squares were 7.324,766.858, and the P values were 0.026,0.001). Conclusion Rifampicin resistant tuberculosis has became an important challenge in the prevention and control of tuberculosis in economic undeveloped areas. Standard treatment and infection control should be further strengthened to reduce the occurrence of drug resistance,young and middle-aged population and cases in urban and neighboring suburbs should be the key populations.

Key words: Tuberculosis,pulmonary, Tuberculosis,multidrug-resistant, Rifampicin, Epidemiologic study characteristics as topic

WANG Meng, WAN Yi-you, XIE Tian, LI Jian-hua, RUAN Yun-zhou, LIU Yue-yuan, HU Jia, FENG De-an, GUO Hui-ying, LI Ren-zhong. Analysis of the epidemiological characteristics of rifampicin-resistant pulmonary tuberculosis in Ganzhou, Jiangxi from 2019 to 2020[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1287-1291. doi: 10.3969/j.issn.1000-6621.2021.12.010

Figures/Tables 4

References 12

[1]	李仁忠. 我国耐多药结核病防治管理中的常见问题及对策. 中国防痨杂志, 2018, 40(6):553-556. doi: 10.3969/j.issn.1000-6621.2018.06.001. doi: 10.3969/j.issn.1000-6621.2018.06.001
[2]	赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 94.
[3]	陈明亭, 李仁忠, 阮云洲. 耐多药结核病防治标准化培训教程. 北京: 人民卫生出版社, 2015.
[4]	Shah NS, Grace Lin SY, Barry PM, et al. Clinical impact on Tuberculosis treatment outcomes of discordance between molecular and growth-based assays for rifampin resistence, California 2003—2013. Open Forum Infect Dis, 2016, 3(3):ofw150. doi: 10.1093/ofid/ofw150. doi: 10.1093/ofid/ofw150 URL
[5]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[6]	刘静, 肖慧霞, 田晓梅, 等. GeneXpert MTB/RIF技术对宁夏地区快速发现肺结核及利福平耐药患者的应用效果评价. 中国防痨杂志, 2021, 43(8):783-789. doi: 10.3969/j.issn.1000-6621.2021.08.006. doi: 10.3969/j.issn.1000-6621.2021.08.006
[7]	柳正卫, 彭颖, 张明五, 等. 浙江省推广基于GeneXpert MTB/RIF检测的结核病诊断流程的效果分析. 中国防痨杂志, 2021, 43(8):790-795. doi: 10.3969/j.issn.1000-6621.2021.08.007. doi: 10.3969/j.issn.1000-6621.2021.08.007
[8]	应潜, 黄文辉, 陈小菁, 等. 282例肺结核患者结核分枝杆菌耐药基线调查及耐多药结核病影响因素分析. 现代预防医学, 2018, 45(19):3597-3600,3604.
[9]	潘虹, 李腾根, 周银古, 等. 2014—2017年新余市结核病耐药特征及影响因素分析. 现代预防医学, 2018, 45(4):155-158.
[10]	何琳, 唐诗邈, 曹宏伟, 等. 辽宁省耐多药结核病可疑者筛查及病人发现情况分析. 医学动物防制, 2020, 36(2):103-106.
[11]	李晨, 丁松宁, 杨晨, 等. 南京市耐多药肺结核患者的发现及纳入治疗情况分析. 现代预防医学, 2017, 44(14):2672-2675.
[12]	Su W, Ruan YZ, Li T, et al. Characteristics of rifampicin-resistant tuberculosis detection in China,2015—2019. Infect Dis Poverty, 2021, 10(1):99. doi: 10.1186/s40249-021-00883-8. doi: 10.1186/s40249-021-00883-8 URL

年份	肺结核 (例)	病原学阳性		固体培养耐药筛查		Xpert耐药筛查		筛查合计		利福平耐药
年份	肺结核 (例)	例数	阳性率 (%)	例数	构成比 (%)	例数	构成比 (%)	例数	筛查率 (%)	例数	耐药率 (%)
2019	5790	3013	52.04	110	4.10	2571	95.90	2681	88.98	160	5.97
2020	4718	2884	61.13	6	0.21	2808	99.79	2814	97.57	145	5.15
合计	10508	5897	56.12	116	2.11	5379	97.89	5495	93.18	305	5.55

来源分类	2019年			2020年			合计
来源分类	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)
新发病原学阳性	2126	70	3.29	2318	81	3.49	4444	151	3.40
复治病原学阳性	519	84	16.18	532	70	13.16	1051	154	14.65
合计	2645	154	5.82	2850	151	5.30	5495	305	5.55

特征	2019年			2020年			合计
特征	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)
性别
男性	2083	125	6.00	2240	122	5.45	4323	247	5.71
女性	562	29	5.16	610	29	4.75	1172	58	4.95
年龄组(岁)
0~19	115	5	4.35	99	3	3.03	214	8	3.74
20~59	1542	94	6.10	1644	105	6.39	3186	199	6.25
≥60	988	55	5.57	1107	43	3.88	2095	98	4.68
合计	2645	154	5.82	2850	151	5.30	5495	305	5.55

县(区)	2019年			2020年			合计
县(区)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)	耐药筛查 (例)	利福平耐药(例)	耐药率 (%)
章贡区	276	28	10.14	269	17	6.32	545	45	8.26
南康区	191	15	7.85	140	15	10.71	331	30	9.06
赣县区	108	10	9.26	218	8	3.67	326	18	5.52
信丰县	140	11	7.86	313	14	4.47	453	25	5.52
大余县	82	5	6.10	117	7	5.98	199	12	6.03
上犹县	160	4	2.50	118	5	4.24	278	9	3.24
崇义县	43	2	4.65	47	4	8.51	90	6	6.67
安远县	118	7	5.93	88	4	4.55	206	11	5.34
龙南县	179	10	5.59	194	9	4.64	373	19	5.09
定南县	85	0	0.00	54	5	9.26	139	5	3.60
全南县	50	3	6.00	73	3	4.11	123	6	4.88
宁都县	139	5	3.60	138	6	4.35	277	11	3.97
于都县	305	24	7.87	336	17	5.06	641	41	6.40
兴国县	210	12	5.71	237	17	7.17	447	29	6.49
会昌县	148	3	2.03	132	5	3.79	280	8	2.86
寻乌县	87	2	2.30	113	7	6.19	200	9	4.50
石城县	135	2	1.48	87	1	1.15	222	3	1.35
瑞金市	189	11	5.82	176	7	3.98	365	18	4.93
赣州市	2645	154	5.82	2850	151	5.30	5495	305	5.55

[1]	ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923.
[2]	CAO Pan, LIANG Kuang-li, YUAN Ji-xin, LI Yong-bo, CHEN Rui, ZHANG Zhi-fei, WU Qian-hong. Analysis of CT findings in patients with initial and retreated cavernous rifampicin-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 694-701.
[3]	RUAN Yun-zhou, SU Wei, JIANG Jia-wen, LI Ren-zhong. The effect of case finding of pulmonary tuberculosis and rifampicin resistance tuberculosis with GeneXpert MTB/RIF test in economic undeveloped areas [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1275-1279.
[4]	FANG Mu-tong, SU You-feng, MAO Zhi, ZHANG Hong-yi, ZENG Jian-feng, ZENG Jian, CAO Wei-peng, WANG Zhong-yuan. Analysis of phenotypic drug sensitivity test of rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1159-1163.
[5]	XU Zu-hui, LIU Li-qin, WANG Qiao-zhi, XU Sheng-hui, BAI Li-qiong. Study on epidemiological characteristics and influencing factors of pathogen positive hospitalized pulmonary tuberculosis patients with extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1164-1170.
[6]	LUO Hui, RUAN Yun-zhou, ZHAO A-li, YUAN Rong, HE Xiao-mou, LI Ren-zhong. Analysis of the effect of patients care on the level of sputum specimens submitted for examination among outpatient follow-up of rifampicin-resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1046-1051.
[7]	DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955.
[8]	YIN Zhe, HE Xiang-yan, LI Qi-feng, LIU Ya-jie, ZHANG Yan, LI De-yang, Jiayina· Lazibieke, Gulinazhaer· Aikebaier, CAO Ming-qin. Spatial-temporal analysis of smear-positive pulmonary tuberculosis in Xinjiang Uygur Autonomous Region from 2011 to 2015 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 597-603.
[9]	XIAO Xiao, CHEN Jing, LI Xiang-qun, XIA Zhen, LUAN Rui-rong, RAO Li-xin, SHEN Xin. Analysis of the epidemiological characteristics of tuberculosis students in Shanghai from 2009 to 2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 498-502.
[10]	LAI Keng,WU Gui-feng,LEI Yu,XIE Wei,WANG Ting,ZHONG Min-er,DU Yu-hua. Analysis of spatial distribution characteristics of tuberculosis in Guangzhou from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 327-334.
[11]	YAO Jing, GU Kai-kan, LI Zhi-hong, HAN Zhi-ying, ZHANG Huai-qing. A comparative analysis of the epidemic characteristics of tuberculosis in elderly and non-elderly in Jing’an District, Shanghai from 2014 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1323-1328.
[12]	LIU Er-yong, ZHOU Lin, XUE Xiao, LIU Chun-fa, BAI Li-qiong, LU Wei, ZHANG Tian-hua, CHENG Shi-ming. Evaluation of treatment effect and safety of rifampicin capsule (Ⅱ) on pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(10): 1092-1099.
[13]	Hui CHEN,Yin-yin XIA,Can-you ZHANG,Jun CHENG,Hui ZHANG. Epidemic trends and characteristics of pulmonary tuberculosis in students in China from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 662-668.
[14]	Ying PENG,Lu TANG,Xin-fa PEI,Xue-ZHi ZHANG,Bai-feng LIN,Li CHEN,Yan-ling YU,Fa-bin LI. Genotypic and transmission characteristics of Mycobacterium tuberculosis in Wuchang City, Heilongjiang Province [J]. Chinese Journal of Antituberculosis, 2019, 41(3): 315-321.
[15]	Yuan LIU,Jun ZHOU,Xiao-li CUI,Jia-yuan LEI,Guo-lian ZHAO,Li-yun DANG. The relationship between false-positive rifampicin resistant results of GeneXpert MTB/RIF and very low bacterial load in the clinical samples [J]. Chinese Journal of Antituberculosis, 2019, 41(2): 176-180.